Latest news

• Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

  In the phase 3 BLOCKSTONE study, Xofluza achieved its primary endpoint of fewer people testing positive for flu when given as a post-exposure prophylaxis treatment. ... Xofluza was first approved by the FDA last year, and is available as a treatment for

• Roche’s flu pill Xofluza moves closer towards EU approval

  The CHMP has recommended Xofluza (baloxavir marboxil) for approval in the EU as a treatment for uncomplicated influenza patients aged 12 years and above. ... Separately, Xofluza has been recommended for approval in the EU for post-exposure prophylaxis of

• Roche scores another FDA approval for Xofluza

  It demonstrated that Xofluza significantly reduced the time of improvement of flu symptoms, including in people with flu type B virus. ... However, similar efficacy results were seen between Xofluza and oseltamivir in relation to duration of symptoms

• Roche’s flu drug Xofluza scores phase 3 primary endpoint

  The trial also observed Xofluza in household members who are at high risk of flu-associated complications and children under 12 years of age. ... Xofluza was approved by the  FDA last year, and is available as a treatment for acute, uncomplicated

• Roche’s new flu pill Xofluza approved in US

  Xofluza is given as a convenient single (one time) dose compared to Tamiflu’s twice daily dosing. ... Xofluza significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir.